Respiratory Syncytial Virus (RSV) Infection Clinical Trials

A listing of Respiratory Syncytial Virus (RSV) Infection medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
Featured trial
A 5 day course of an investigational antiviral tablet for those positive to RSV.

5 visits over 2 weeks testing an investigational medication for RSV. Must be between 18-75 years and experiencing cold and flu like symptoms.  

  • 120 views
  • 23 Nov, 2020
  • 1 location
Featured trial
RSV Vaccine Study - M2204

Receive up to $1,035 in compensation and study related care to participate in an RSV Vaccine study. If you are 60 years old or older you may be eligible to receive an RSV Vaccine at no cost.Compensation:- Compensation for up to $1,035- Study related care at no costWho may participate …

  • 0 views
  • 02 Aug, 2022
  • 1 location
Featured trial
Flu Vaccine (FDA Approved) and RSV Vaccine study. - F6000

Flu Vaccine (FDA Approved) and RSV Vaccine Study. Receive up to $975 in compensation and study related care. If you are 60 years old or older you may be eligible to receive a Flu Vaccine (FDA Approved) and an RSV Vaccine at no cost. Compensation: Compensation for up to $975 …

  • 0 views
  • 09 Jun, 2022
  • 1 location
Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life (VAS00006)

lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth referred to as RSV LRTI hospitalizations) in all infants under 12 months of age who are not eligible to receive

Accepts healthy volunteers
  • 109 views
  • 18 Nov, 2022
  • 25 locations
A Phase IIIb Randomized Open-label Study of Nirsevimab (Versus no Intervention) in Preventing Hospitalizations Due to Respiratory Syncytial Virus in Infants (HARMONIE) (VAS00006)

lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth referred to as RSV LRTI hospitalizations) in all infants under 12 months of age who are not eligible to receive

Accepts healthy volunteers
  • 0 views
  • 20 Oct, 2022
  • 26 locations
A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants

The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants. It is hypothesized that clesrovimab will reduce the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through …

Accepts healthy volunteers
  • 6 views
  • 23 Oct, 2022
  • 174 locations
MVA-BN-RSV Vaccine Trial

Phase 3 randomized, double blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults >=60 years of age

Accepts healthy volunteers
  • 56 views
  • 07 Oct, 2022
  • 95 locations
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease

This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).

  • 0 views
  • 28 Oct, 2022
  • 95 locations
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract (RSVTx)

This is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and symptoms of URTI

  • 0 views
  • 29 Oct, 2022
  • 71 locations
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

The primary objectives of this study are to evaluate the tolerability and reactogenicity of a single injection of up to 5 dose levels of mRNA-1345 in younger adults, women of child-bearing potential, and older adults including Japanese older adults; of 3 injections of the middle dose level of mRNA-1345 given …

Accepts healthy volunteers
body mass index
vaccination
  • 348 views
  • 14 Jul, 2022
  • 21 locations